Drupal.behaviors.print = function(context) {window.print();window.close();}>
Qiagen, Lilly Partner to Develop JAK2 Companion Test for Investigational Blood Cancer Drug
September 07, 2011
Qiagen, Lilly Partner to Develop JAK2 Companion Test for Investigational Blood Cancer Drug
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Qiagen, Eli Lilly Enter CDx Deal
February 14, 2013 / GenomeWeb Daily News
Dx Focus: Clarient to Offer Qiagen Therascreen KRAS Test as Erbitux CDx
January 31, 2013 / PCR Insider
Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter
Qiagen Enters Companion Dx Market with Approval of KRAS Test Kit for Erbitux; LDT Impact Unknown
July 11, 2012 / Pharmacogenomics Reporter
FDA Clears Qiagen KRAS Test as CDx for Erbitux
July 9, 2012 / GenomeWeb Daily News